Omics profiling in precision oncology

Molecular and Cellular Proteomics

Volumn 15, Issue 8, 2016, Pages 2525-2536

  Yu, Kun Hsing ^a   Snyder, Michael ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMICS; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENOMICS; HUMAN; LUNG CANCER; METABOLOMICS; ONCOLOGY; PANCREAS CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; BIOLOGY; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES; PROGNOSIS;

COMPUTATIONAL BIOLOGY; GENOMICS; HUMANS; METABOLOMICS; MUTATION; NEOPLASMS; PRECISION MEDICINE; PROGNOSIS; PROTEOMICS;

EID: 84982823011     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.O116.059253     Document Type: Review

References (126)

1. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015) Global cancer statistics, 2012. CA 65, 87-108
2. Siegel, R. L., Miller, K. D., and Jemal, A. (2015) Cancer statistics, 2015. CA 65, 5-29
3. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: The next generation. Cell 144, 646-674
4. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70
5. National Research Council Committee on A Framework for Developing a New Taxonomy of Disease (2011) Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease, National Academies Press (US).
6. Snyder, M. (2016) Genomics and Personalized Medicine: What Everyone Needs to Know, Oxford University Press
7. Collins, F. S., and Varmus, H. (2015) A new initiative on precision medicine. The New England journal of medicine 372, 793-795
8. Ashley, E. A. (2015) The precision medicine initiative: A new national effort. JAMA 313, 2119-2120
9. Holzinger, A., Dehmer, M., and Jurisica, I. (2014) Knowledge Discovery and interactive Data Mining in Bioinformatics-State-of-the-Art, future challenges and research directions. BMC bioinformatics 15, I1
10. Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J. M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genetics 45, 1113-1120
11. Zhang, J., Baran, J., Cros, A., Guberman, J. M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., Wong-Erasmus, M., Yao, L., and Kasprzyk, A. (2011) International Cancer Genome Consortium Data Portal - A one-stop shop for cancer genomics data. Database 2011, bar026
12. Larranaga, P., Calvo, B., Santana, R., Bielza, C., Galdiano, J., Inza, I., Lozano, J. A., Armananzas, R., Santafe, G., Perez, A., and Robles, V. (2006) Machine learning in bioinformatics. Briefings Bioinformatics 7, 86-112
13. Bellazzi, R., and Zupan, B. (2008) Predictive data mining in clinical medicine: Current issues and guidelines. Int. J. Medical Informatics 77, 81-97
14. Vucic, E. A., Thu, K. L., Robison, K., Rybaczyk, L. A., Chari, R., Alvarez, C. E., and Lam, W. L. (2012) Translating cancer 'omics' to improved outcomes. Genome Res. 22, 188-195
15. Lakhani, S. R., and Ashworth, A. (2001) Microarray and histopathological analysis of tumours: The future and the past? Nat. Rev. Cancer 1, 151-157
16. Clinical Lung Cancer Genome, P., and Network Genomic, M. (2013) A genomics-based classification of human lung tumors. Sci. Translational Med. 5, 209ra153
17. Abeloff, M., Armitage, J., Niederhuber, J., Kastan, M., and Mckenna, W. (2004) Clinical Oncology. Philadelphia, PA: Churchill Livingstone. Elsevier
18. Roberts, T. E., Hasleton, P. S., Musgrove, C., Swindell, R., and Lawson, R. A. (1992) Vascular invasion in non-small cell lung carcinoma. J. Clin. Pathol. 45, 591-593
19. Ogawa, J., Tsurumi, T., Yamada, S., Koide, S., and Shohtsu, A. (1994) Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 73, 1177-1183
20. Kumar, V., Abbas, A. K., Fausto, N., and Aster, J. C. (2014) Robbins and cotran pathologic basis of disease, Professional Edition: Expert Consult- Online, Elsevier Health Sciences.
21. Baish, J. W., and Jain, R. K. (2000) Fractals and cancer. Cancer Res. 60, 3683-3688
22. Sobin, L. H., Gospodarowicz, M. K., Wittekind, C., and International Union against Cancer. (2010) TNM classification of malignant tumours, 7th Ed., Wiley-Blackwell, Chichester, West Sussex, UK ; Hoboken, NJ
23. Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., Sobin, L., International Association for the Study of Lung Cancer International Staging, C., and Participating, I. (2007) The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thoracic Oncol. 2, 706-714
24. Greene, F. L. (2002) AJCC cancer staging manual, Springer Science & Business Media.
25. Edge, S. B., and American Joint Committee on Cancer. (2010) AJCC cancer staging manual, 7th Ed., Springer, New York.
26. Gronchi, A., Miceli, R., Shurell, E., Eilber, F. C., Eilber, F. R., Anaya, D. A., Kattan, M. W., Honore, C., Lev, D. C., Colombo, C., Bonvalot, S., Mariani, L., and Pollock, R. E. (2013) Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: Histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J. Clin. Oncol. 31, 1649-1655
27. Delahunt, B., McKenney, J. K., Lohse, C. M., Leibovich, B. C., Thompson, R. H., Boorjian, S. A., and Cheville, J. C. (2013) A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am. J. Surg. Pathol. 37, 311-322
28. Ramos-Vara, J. A., and Miller, M. A. (2014) When tissue antigens and antibodies get along: Revisiting the technical aspects of immunohistochemistry-the red, brown, and blue technique. Veterinary Pathol. 51, 42-87
29. Chiang, S. C., Han, C. L., Yu, K. H., Chen, Y. J., and Wu, K. P. (2013) Prioritization of cancer marker candidates based on the immunohistochemistry staining images deposited in the human protein atlas. PloS One 8, e81079
30. Stang, A., Pohlabeln, H., Muller, K. M., Jahn, I., Giersiepen, K., and Jockel, K. H. (2006) Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer 52, 29-36
31. Grilley-Olson, J. E., Hayes, D. N., Moore, D. T., Leslie, K. O., Wilkerson, M. D., Qaqish, B. F., Hayward, M. C., Cabanski, C. R., Yin, X., Socinski, M. A., Stinchcombe, T. E., Thorne, L. B., Allen, T. C., Banks, P. M., Beasley, M. B., Borczuk, A. C., Cagle, P. T., Christensen, R., Colby, T. V., Deblois, G. G., Elmberger, G., Graziano, P., Hart, C. F., Jones, K. D., Maia, D. M., Miller, C. R., Nance, K. V., Travis, W. D., and Funkhouser, W. K. (2013) Validation of interobserver agreement in lung cancer assessment: Hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: The 2004 World Health Organization classification and therapeutically relevant subsets. Arch. Pathol. Lab. Med. 137, 32-40
32. Wall, D. P., and Tonellato, P. J. (2012) The future of genomics in pathology. F1000 Med. Reports 4, 14
33. Hayes, D. F. (2013) OMICS-based personalized oncology: If it is worth doing, it is worth doing well! BMC Med. 11, 221
34. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., and Kinzler, K. W. (2013) Cancer genome landscapes. Science 339, 1546-1558
35. Gehlenborg, N., O'Donoghue, S. I., Baliga, N. S., Goesmann, A., Hibbs, M. A., Kitano, H., Kohlbacher, O., Neuweger, H., Schneider, R., Tenenbaum, D., and Gavin, A. C. (2010) Visualization of omics data for systems biology. Nat. Methods 7, S56-68
36. McShane, L. M., Cavenagh, M. M., Lively, T. G., Eberhard, D. A., Bigbee, W. L., Williams, P. M., Mesirov, J. P., Polley, M. Y., Kim, K. Y., Tricoli, J. V., Taylor, J. M., Shuman, D. J., Simon, R. M., Doroshow, J. H., and Conley, B. A. (2013) Criteria for the use of omics-based predictors in clinical trials. Nature 502, 317-320
37. Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., and Workman, P. (2013) Personalized cancer medicine: Molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Therapeutics 93, 252-259
38. Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., Galens, K. G., Murphy, D., Zhang, T., Kann, L., Sausen, M., Angiuoli, S. V., Diaz, L. A., Jr., and Velculescu, V. E. (2015) Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Translational Med. 7, 283ra253
39. Sawyers, C. (2004) Targeted cancer therapy. Nature 432, 294-297
40. Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Ji, W., Zhou, Y., and Lu, J. (2012) A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. Am. J. Human Gen. 91, 384-390
41. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., and Meyerson, M. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500
42. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., and Hirth, P. (2012) Vemurafenib: The first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discovery 11, 873-886
43. Tanizaki, J., Okamoto, I., Okamoto, K., Takezawa, K., Kuwata, K., Yamaguchi, H., and Nakagawa, K. (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J. Thoracic Oncol. 6, 1624-1631
44. Pao, W., and Girard, N. (2011) New driver mutations in non-small-cell lung cancer. Lancet. Oncol. 12, 175-180
45. Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., and Nishio, K. (2014) Targeting MET amplification as a new oncogenic driver. Cancers 6, 1540-1552
46. Heist, R. S., Sequist, L. V., and Engelman, J. A. (2012) Genetic changes in squamous cell lung cancer: A review. J. Thoracic Oncol. 7, 924-933
47. Kohno, T., Tsuta, K., Tsuchihara, K., Nakaoku, T., Yoh, K., and Goto, K. (2013) RET fusion gene: Translation to personalized lung cancer therapy. Cancer Sci. 104, 1396-1400
48. Scheffler, M., Schultheis, A., Teixido, C., Michels, S., Morales-Espinosa, D., Viteri, S., Hartmann, W., Merkelbach-Bruse, S., Fischer, R., Schildhaus, H. U., Fassunke, J., Sebastian, M., Serke, M., Kaminsky, B., Randerath, W., Gerigk, U., Ko, Y. D., Kruger, S., Schnell, R., Rothe, A., Kropf-Sanchen, C., Heukamp, L., Rosell, R., Buttner, R., and Wolf, J. (2015) ROS1 rearrangements in lung adenocarcinoma: Prognostic impact, therapeutic options and genetic variability. Oncotarget 6, 10577-10585
49. Zhao, W., Choi, Y.-L., Song, J.-Y., Zhu, Y., Xu, Q., Zhang, F., Jiang, L., Cheng, J., Zheng, G., and Mao, M. (2016) ALK, ROS1 and RET Rearrangements in Lung Squamous Cell Carcinoma Are Very Rare. Lung Cancer 94, 22-27
50. National Comprehensive Cancer Network (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) National Comprehensive Cancer Network.
51. Singhal, S., Vachani, A., Antin-Ozerkis, D., Kaiser, L. R., and Albelda, S. M. (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin. Cancer Res. 11, 3974-3986
52. Chin, L., and Gray, J. W. (2008) Translating insights from the cancer genome into clinical practice. Nature 452, 553-563
53. Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., Cheng, Y., Clark, M. J., Im, H., Habegger, L., Balasubramanian, S., O'Huallachain, M., Dudley, J. T., Hillenmeyer, S., Haraksingh, R., Sharon, D., Euskirchen, G., Lacroute, P., Bettinger, K., Boyle, A. P., Kasowski, M., Grubert, F., Seki, S., Garcia, M., Whirl-Carrillo, M., Gallardo, M., Blasco, M. A., Greenberg, P. L., Snyder, P., Klein, T. E., Altman, R. B., Butte, A. J., Ashley, E. A., Gerstein, M., Nadeau, K. C., Tang, H., and Snyder, M. (2012) Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307
54. Papin, J. A., Stelling, J., Price, N. D., Klamt, S., Schuster, S., and Palsson, B. O. (2004) Comparison of network-based pathway analysis methods. Trends Biotechnol. 22, 400-405
55. Khatri, P., Sirota, M., and Butte, A. J. (2012) Ten years of pathway analysis: Current approaches and outstanding challenges. PLoS Computational Biol. 8, e1002375
56. Iacobuzio-Donahue, C. A. (2009) Epigenetic changes in cancer. Ann. Rev. Pathol. 4, 229-249
57. Jones, P. A., and Takai, D. (2001) The role of DNA methylation in mammalian epigenetics. Science 293, 1068-1070
58. Kouzarides, T. (2007) Chromatin modifications and their function. Cell 128, 693-705
59. Hyun, B. R., McElwee, J. L., and Soloway, P. D. (2015) Single molecule and single cell epigenomics. Methods 72, 41-50
60. Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., and Paul, C. L. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U.S.A. 89, 1827-1831
61. National Cancer Institute TCGA Wiki. (2015) DNA methylation. Retrieved April 15, 2016, from https://wiki.nci.nih.gov/display/TCGA/DNA- methylation
62. Collas, P. (2010) The current state of chromatin immunoprecipitation. Mol. Biotechnol. 45, 87-100
63. Buck, M. J., and Lieb, J. D. (2004) ChIP-chip: Considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. Genomics 83, 349-360
64. Park, P. J. (2009) ChIP-seq: Advantages and challenges of a maturing technology. Nature reviews. Genetics 10, 669-680
65. Euskirchen, G. M., Rozowsky, J. S., Wei, C. L., Lee, W. H., Zhang, Z. D., Hartman, S., Emanuelsson, O., Stolc, V., Weissman, S., Gerstein, M. B., Ruan, Y., and Snyder, M. (2007) Mapping of transcription factor binding regions in mammalian cells by ChIP: Comparison of array- and sequencing- based technologies. Genome Res. 17, 898-909
66. Hinoue, T., Weisenberger, D. J., Lange, C. P., Shen, H., Byun, H. M., Van Den Berg, D., Malik, S., Pan, F., Noushmehr, H., van Dijk, C. M., Tollenaar, R. A., and Laird, P. W. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22, 271-282
67. Thol, F., Damm, F., Ludeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A., and Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J. Clin. Oncol. 29, 2889-2896
68. Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., Sanchez- Cespedes, M., Assenov, Y., Muller, F., Bock, C., Taron, M., Mora, J., Muscarella, L. A., Liloglou, T., Davies, M., Pollan, M., Pajares, M. J., Torre, W., Montuenga, L. M., Brambilla, E., Field, J. K., Roz, L., Lo Iacono, M., Scagliotti, G. V., Rosell, R., Beer, D. G., and Esteller, M. (2013) A prognostic DNA methylation signature for stage I non-smallcell lung cancer. J. Clin. Oncol. 31, 4140-4147
69. Maruyama, R., Toyooka, S., Toyooka, K. O., Virmani, A. K., Zochbauer- Muller, S., Farinas, A. J., Minna, J. D., McConnell, J., Frenkel, E. P., and Gazdar, A. F. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8, 514-519
70. Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., Brown, G. D., Gojis, O., Ellis, I. O., Green, A. R., Ali, S., Chin, S. F., Palmieri, C., Caldas, C., and Carroll, J. S. (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393
71. Seligson, D. B., Horvath, S., McBrian, M. A., Mah, V., Yu, H., Tze, S., Wang, Q., Chia, D., Goodglick, L., and Kurdistani, S. K. (2009) Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174, 1619-1628
72. Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M. C., Hung, T., Argani, P., Rinn, J. L., Wang, Y., Brzoska, P., Kong, B., Li, R., West, R. B., van de Vijver, M. J., Sukumar, S., and Chang, H. Y. (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076
73. Wang, Z., Gerstein, M., and Snyder, M. (2009) RNA-Seq: A revolutionary tool for transcriptomics. Nature Rev. Genetics 10, 57-63
74. Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., and Gilad, Y. (2008) RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 18, 1509-1517
75. Ozsolak, F., and Milos, P. M. (2011) RNA sequencing: Advances, challenges and opportunities. Nature Rev. Genetics 12, 87-98
76. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. (1999) Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286, 531-537
77. Iorio, F., Rittman, T., Ge, H., Menden, M., and Saez-Rodriguez, J. (2013) Transcriptional data: A new gateway to drug repositioning? Drug Discovery Today 18, 350-357
78. Quackenbush, J. (2006) Microarray analysis and tumor classification. New Engl. J. Med. 354, 2463-2472
79. Huang, H., Liu, C. C., and Zhou, X. J. (2010) Bayesian approach to transforming public gene expression repositories into disease diagnosis databases. Proc. Natl. Acad. Sci. U.S.A. 107, 6823-6828
80. Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M., Iannettoni, M. D., Orringer, M. B., and Hanash, S. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8, 816-824
81. Chudin, E., Lozach, J., Fan, J.-B., and Bibikova, M. (2011) Gene expression profiles to predict relapse of prostate cancer. In: U.S. Patent and Trademark Office, ed., US.
82. Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., Johnson, L. A., Robinson, J., Verhaak, R. G., Sougnez, C., Onofrio, R. C., Ziaugra, L., Cibulskis, K., Laine, E., Barretina, J., Winckler, W., Fisher, D. E., Getz, G., Meyerson, M., Jaffe, D. B., Gabriel, S. B., Lander, E. S., Dummer, R., Gnirke, A., Nusbaum, C., and Garraway, L. A. (2010) Integrative analysis of the melanoma transcriptome. Genome Res. 20, 413-427
83. Edgren, H., Murumagi, A., Kangaspeska, S., Nicorici, D., Hongisto, V., Kleivi, K., Rye, I. H., Nyberg, S., Wolf, M., Borresen-Dale, A. L., and Kallioniemi, O. (2011) Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 12, R6
84. Nacu, S., Yuan, W., Kan, Z., Bhatt, D., Rivers, C. S., Stinson, J., Peters, B. A., Modrusan, Z., Jung, K., Seshagiri, S., and Wu, T. D. (2011) Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med. Genomics 4, 11
85. Tyers, M., and Mann, M. (2003) From genomics to proteomics. Nature 422, 193-197
86. Aebersold, R., and Mann, M. (2003) Mass spectrometry-based proteomics. Nature 422, 198-207
87. Domon, B., and Aebersold, R. (2006) Mass spectrometry and protein analysis. Science 312, 212-217
88. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., Macneill, J., Ren, J. M., Yuan, J., Bakalarski, C. E., Villen, J., Kornhauser, J. M., Smith, B., Li, D., Zhou, X., Gygi, S. P., Gu, T. L., Polakiewicz, R. D., Rush, J., and Comb, M. J. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203
89. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., Wu, Y. L., Thomas, M., O'Byrne, K. J., Moro-Sibilot, D., Camidge, D. R., Mok, T., Hirsh, V., Riely, G. J., Iyer, S., Tassell, V., Polli, A., Wilner, K. D., and Janne, P. A. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl. J. Med. 368, 2385-2394
90. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., Kim, S., Davies, S. R., Wang, S., Wang, P., Kinsinger, C. R., Rivers, R. C., Rodriguez, H., Townsend, R. R., Ellis, M. J., Carr, S. A., Tabb, D. L., Coffey, R. J., Slebos, R. J., Liebler, D. C., and Nci, C. (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382-387
91. LaBaer, J., and Ramachandran, N. (2005) Protein microarrays as tools for functional proteomics. Current Opinion Chem. Biol. 9, 14-19
92. Haab, B. B. (2003) Methods and applications of antibody microarrays in cancer research. Proteomics 3, 2116-2122
93. Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., and Gallagher, W. M. (2010) Antibody-based proteomics: Fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 10, 605-617
94. Spurrier, B., Ramalingam, S., and Nishizuka, S. (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat. Protocols 3, 1796-1808
95. Vazquez-Martin, A., Colomer, R., and Menendez, J. A. (2007) Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur. J. Cancer 43, 1117-1124
96. Bast, R. C., Jr., Hennessy, B., and Mills, G. B. (2009) The biology of ovarian cancer: New opportunities for translation. Nat. Rev. Cancer 9, 415-428
97. Rochfort, S. (2005) Metabolomics reviewed: A new 'omics' platform technology for systems biology and implications for natural products research. J. Natural Products 68, 1813-1820
98. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-1033
99. Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., and Di Leo, A. (2007) Metabolomics: Available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 25, 2840-2846
100. Shulaev, V. (2006) Metabolomics technology and bioinformatics. Briefings in Bioinformatics 7, 128-139
101. Chan, E. C., Koh, P. K., Mal, M., Cheah, P. Y., Eu, K. W., Backshall, A., Cavill, R., Nicholson, J. K., and Keun, H. C. (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361
102. Blekherman, G., Laubenbacher, R., Cortes, D. F., Mendes, P., Torti, F. M., Akman, S., Torti, S. V., and Shulaev, V. (2011) Bioinformatics tools for cancer metabolomics. Metabolomics : Official J. Metabolomic Soc. 7, 329-343
103. Beckonert, O., Keun, H. C., Ebbels, T. M., Bundy, J., Holmes, E., Lindon, J. C., and Nicholson, J. K. (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protocols 2, 2692-2703
104. Bertram, H. C., Eggers, N., and Eller, N. (2009) Potential of human saliva for nuclear magnetic resonance-based metabolomics and for healthrelated biomarker identification. Anal. Chem. 81, 9188-9193
105. Smolinska, A., Blanchet, L., Buydens, L. M., and Wijmenga, S. S. (2012) NMR and pattern recognition methods in metabolomics: From data acquisition to biomarker discovery: A review. Anal. Chim. Acta 750, 82-97
106. Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., and Scalbert, A. (2013) HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 41, D801-807
107. Labuschagne, C. F., van den Broek, N. J., Mackay, G. M., Vousden, K. H., and Maddocks, O. D. (2014) Serine, but not glycine, supports onecarbon metabolism and proliferation of cancer cells. Cell Reports 7, 1248-1258
108. Lv, W., and Yang, T. (2012) Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clin. Biochem. 45, 127-133
109. Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., and Schultz, N. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling 6, pl1
110. Nibbe, R. K., Koyuturk, M., and Chance, M. R. (2010) An integrative -omics approach to identify functional sub-networks in human colorectal cancer. PLoS Computational Biol. 6, e1000639
111. Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat. Genetics 45, 1127-1133
112. Kristensen, V. N., Lingjaerde, O. C., Russnes, H. G., Vollan, H. K., Frigessi, A., and Borresen-Dale, A. L. (2014) Principles and methods of integrative genomic analyses in cancer. Nature Revi. Cancer 14, 299-313
113. Dawson, S. J., Rueda, O. M., Aparicio, S., and Caldas, C. (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 32, 617-628
114. Palucka, K., and Banchereau, J. (2012) Cancer immunotherapy via dendritic cells. Nature Rev. Cancer 12, 265-277
115. Schumacher, T. N., and Schreiber, R. D. (2015) Neoantigens in cancer immunotherapy. Science 348, 69-74
116. Mellman, I., Coukos, G., and Dranoff, G. (2011) Cancer immunotherapy comes of age. Nature 480, 480-489
117. Disis, M. L. (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol., Immunotherapy 60, 433-442
118. Pao, W., and Hutchinson, K. E. (2012) Chipping away at the lung cancer genome. Nature Med. 18, 349-351
119. Bedard, P. L., Hansen, A. R., Ratain, M. J., and Siu, L. L. (2013) Tumour heterogeneity in the clinic. Nature 501, 355-364
120. Merlo, L. M., Pepper, J. W., Reid, B. J., and Maley, C. C. (2006) Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924-935
121. Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., Martinez, P., Phillimore, B., Begum, S., Rabinowitz, A., Spencer-Dene, B., Gulati, S., Bates, P. A., Stamp, G., Pickering, L., Gore, M., Nicol, D. L., Hazell, S., Futreal, P. A., Stewart, A., and Swanton, C. (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics 46, 225-233
122. Marusyk, A., and Polyak, K. (2010) Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 1805, 105-117
123. Kim, C., and Paik, S. (2010) Gene-expression-based prognostic assays for breast cancer. Nature reviews. Clinical Oncol. 7, 340-347
124. La Thangue, N. B., and Kerr, D. J. (2011) Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nature reviews. Clin. Oncol. 8, 587-596
125. Chao, T. C., Hansmeier, N., and Halden, R. U. (2010) Towards proteome standards: The use of absolute quantitation in high-throughput biomarker discovery. J. Proteomics 73, 1641-1646
126. Moch, H., Blank, P. R., Dietel, M., Elmberger, G., Kerr, K. M., Palacios, J., Penault-Llorca, F., Rossi, G., and Szucs, T. D. (2012) Personalized cancer medicine and the future of pathology. Virchows Archiv 460, 3-8.